3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
3
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lung Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Metastatic NUT Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
etoposide phosphate
×
Clear all
NCT00776802
2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2
Withdrawn